BPTH (Bio-Path Holdings) Institutional Ownership: 0.37% (As of Jul. 08, 2026)


What is Bio-Path Holdings Institutional Ownership?

Bio-Path Holdings BPTH +5.26% Institutional Ownership is 0.37% as of Jul. 08, 2026. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Bio-Path Holdings's institutional ownership is 0.37%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Bio-Path Holdings's Insider Ownership is 18.82%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Bio-Path Holdings's Float Percentage Of Total Shares Outstanding is 99.99%.

Bio-Path Holdings Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Bio-Path Holdings's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Path Holdings Institutional Ownership Chart

Bio-Path Holdings Historical Data

The historical data trend for Bio-Path Holdings can be seen below:

2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28
Institutional Ownership 0.44 0.55 0.55 0.48 0.41 0.39 0.34 0.25 0.25 0.03

Bio-Path Holdings Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.37% mean?
Bio-Path Holdings (BPTH) has a Institutional Ownership of 0.37% as of Jul. 08, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Bio-Path Holdings and its competitors.
Is Bio-Path Holdings' Institutional Ownership too high?
Bio-Path Holdings' current Institutional Ownership is 0.37%.
How does Bio-Path Holdings' Institutional Ownership compare to VBIO and HEPA?
Bio-Path Holdings' Institutional Ownership of 0.37% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Bio-Path Holdings and its competitors. Bio-Path Holdings's current Institutional Ownership is 0.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current Institutional Ownership of 0.37%. The current Institutional Ownership is 0.37%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current Institutional Ownership is 0.37% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Path Holdings Business Description

Address No. 2407, 625 Stanwix Street, Pittsburgh, PA, USA, 15222
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.